Motesanib diphosphate in progressive differentiated thyroid cancer

Autor: Sherman, Si, Wirth, Lj, Droz, Jp, Hofmann, M, Bastholt, L, Martins, Rg, Licitra, L, Eschenberg, Mj, Sun, Yn, Juan, T, Stepan, De, Schlumberger, Mj, Motesanib Thyroid Cancer Study Group including Lind, P, Pirich, C, Daumerie, C, Baudin, E, Bui, Bn, Conte Devolx, B, Rohmer, V, Schvartz, C, Szabolcs, I, Racz, K, Brandi, Ml, Pinchera, A, Elisei, R, Orlandi, Fabio, Pacini, F, Jarzab, B, Sowinski, J, Jansson, S, Lundell, G, Hallqvist, A, Meier, C, Philippe, J, Agarwala, S, Ali, H, Barrera, J, Boccia, R, Bukowski, R, Burman, K, Clark, O, Davis, T, Hoff, A, Sarlis, N, Jakub, J, Mena, R, Nahleh, Z, Rosen, L, Stephenson, J, Srkalovic, G, Tchekmedyian, N.

Publikováno v: New England Journal of Medicine, Vol. 359, No 1 (2008) pp. 31-42
Sherman, S I, Wirth, L J, Droz, J-P, Hofmann, M, Bastholt, L, Martins, R G, Licitra, L, Eschenberg, M J, Sun, Y-N, Juan, T, Stepan, D E, Schlumberger, M J & Study Group, M T C 2008, ' Motesanib diphosphate in progressive differentiated thyroid cancer ', The New England Journal of Medicine, vol. 359, no. 1, pp. 31-42 . https://doi.org/10.1056/NEJMoa075853

Udgivelsesdato: 2008-Jul-3 BACKGROUND: The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca7ec62fd0d77b607c5390bd8fd6f8ec
https://archive-ouverte.unige.ch/unige:2416

International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

Autor: Mead, GM, Stenning, SP, Cook, P, Fossa, SD, Horwich, A, Kaye, SB, Oliver, RTD, deMulder, PHM, deWit, R, Stoter, G, Sylvester, RJ, Bajorin, DF, Bosl, GJ, Mazumdar, M, Nichols, CR, Amato, R, Pizzocaro, G, Droz, JP, Kramar, A, Daugaard, G, CortesFunes, H, PazAres, L, Levi, JA, Colls, BM, Harvey, VJ, Coppin, C

Publikováno v: Journal of Clinical Oncology, 15(2), 594-603. AMER SOC CLINICAL ONCOLOGY

Purpose: Cisplatin-containing chemotherapy has dramatically improved the outlook for patients with metastatic germ cell tumors (GCT), and overall cure rates now exceed 80%. To make appropriate risk-based decisions about therapy and to facilitate coll

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::ea089d00012f98de987c3f789f105f52
https://research.rug.nl/en/publications/df68b8ba-e5b4-4561-9923-1c90810fcc28

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.